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AICD = activation-induced cell death; HAM/TSP = HTLV-I-associated myelopathy/tropical spastic paraparesis; HTLV-I = human T cell lymphotropic
virus I; IL = interleukin; IL-2R = interleukin-2 receptor; IL-15R = interleukin-15 receptor; NK = natural killer; RA = rheumatoid arthritis; TNF-α =
tumor necrosis factor-α.
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Introduction
Cytokines are crucially involved in the regulation of the
normal human immune response. Furthermore, dysregula-
tion of cytokine expression also has a complex role in the
pathogenesis of autoimmune diseases [1]. In particular,
disordered expression of interleukin (IL)-2, IL-12, IL-17,
IL-18, interferon, and tumor necrosis factor-α (TNF-α) as
well as downstream mediators of inflammation such as
IL-1, IL-6, and inflammatory chemokines have been
invoked as pathogenic elements underlying the
development and maintenance of inflammation and
autoimmunity [2]. These insights concerning cytokine-
mediated inflammation have been translated into the
development of novel therapeutic agents. In particular,
TNF-α has been identified as an important target in the
therapy of such autoimmune diseases as rheumatoid
arthritis (RA), inflammatory bowel disease, and psoriasis
[2]. Such cytokine-directed blockade with anti-TNF-α
monoclonal antibodies or soluble TNF-α receptors has
revolutionized the therapy of these autoimmune diseases.
Nevertheless these TNF-α-directed approaches do not
provide effective therapy for all patients with autoimmune
disease: new therapeutic targets are needed. Recently,
disorders involving interleukin-15 (IL-15) have been shown
in such autoimmune diseases as RA, multiple sclerosis,
ulcerative colitis, celiac syndrome, psoriasis, sarcoidosis,
and hepatitis-C, as well as in diseases associated with the
retrovirus human T cell lymphotropic virus-I (HTLV-I) [3–6].
An array of therapeutic strategies are therefore being
developed to target IL-15, its receptor subunit or its
signaling elements to provide effective therapy for such
autoimmune disorders [7–10].
The contrasting roles of IL-2 and IL-15 in the
life and death of lymphocytes
Two groups simultaneously reported the identification of a
14–15 kDa stimulatory factor acting on T cells and natural
killer (NK) cells that was termed IL-15 [11,12]. The
heterotrimeric IL-15 receptor includes a private IL-15-
specific receptor subunit (IL-15Rα) together with the IL-
2R/IL-15Rβ subunit that is shared with IL-2 and the
common gamma chain (γc) receptor subunit that is also
used by IL-2, IL-4, IL-7, IL-9, and IL-21. As might be
expected from their sharing of the γc and IL-2R/IL-15Rβ
subunits, IL-2 and IL-15 share several biological activities.
However, they also provide distinct and at times contrasting
contributions to the life and death of lymphocytes,
especially in adaptive immune responses [13].
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These shared and contrasting roles can be considered in
relation to a series of goals of the immune system that
include the following: first, the generation of a rapid innate
and adaptive response to invading pathogens; second,
the elimination of autoreactive T cells to yield tolerance to
self, and third, the maintenance of a specific memory
response to pathogens. IL-2 and IL-15 share functions
including the initial stimulation of the proliferation of
activated T and B cells as well as the maintenance and
activation of NK cells. However, IL-2 is pivotally involved in
the maintenance of CD4+, CD25+ T-regulatory cells and in
activation-induced cell death (AICD) – a process that leads
to the elimination of self-reactive T cells. By contrast, IL-15
inhibits IL-2 induced AICD. Furthermore, IL-15 stimulates
the maintenance of CD8+ memory-phenotype T cells,
whereas IL-2 inhibits their persistence in vivo [13–15].
An analysis of mice with disrupted genes for IL-2, IL-15,
and their cytokine receptors supports these competitive
roles for IL-2 and IL-15. In particular, IL-2–/– and IL-2Rα–/–
mice undergo massive enlargement of peripheral lymphoid
organs and develop autoimmune diseases [16]. In
contrast, mice genetically deficient in IL-15 or IL-15Rα do
not manifest lymphoid enlargement, high concentrations of
immunoglobulins, or autoimmune diseases; rather, they
display a marked reduction in the numbers of NK cells and
CD8+ memory T cells [17]. These studies support the
view that through its inhibition of IL-2-mediated AICD and
its role in the maintenance of memory CD8+ T cells, IL-15
favors the persistence of lymphocytes that are of value in
long-lasting specific immune responses to foreign
pathogens. Although these IL-15-mediated immune
responses are of importance in the response to foreign
pathogens, the uncontrolled expression of IL-15 carries
with it the risk to the organism of the survival of
autoreactive T cells that could lead to the development of
autoimmune diseases.
The opposing effects of IL-2 and IL-15 have implications
for immunotherapy. IL-2 is used in the treatment of
patients with metastatic renal cell carcinoma or malignant
melanoma and as a component of vaccines. However,
owing to the role of IL-2 in AICD, the maintenance of
CD4+, CD25+, negative regulatory cells, and its
termination of memory T cell responses, it is not optimal. In
view of these observations with its contrasting role in the
survival of lymphocytes through its inhibitory role in AICD
and its facilitation of the persistence of memory CD8+
cells, IL-15 might be superior to IL-2 in the treatment of
cancer and as a component of vaccines directed against
cancer or infectious agents.
Abnormalities of IL-15 expression in
inflammatory autoimmune diseases
IL-15 is a dangerous inflammatory cytokine that inhibits
self-tolerance mediated by AICD and facilitates the
survival of CD8+ memory T cells, including those that are
self-directed. Furthermore, IL-15 induces TNF-α and IL-1β
[3]. Despite an array of regulatory controls, disordered
IL-15 expression has been observed in patients with a
series of inflammatory autoimmune diseases. McInnes and
colleagues reported abnormalities of IL-15 in RA and have
suggested that IL-15 might precede TNF-α in the cytokine
cascade [3]. In particular, IL-15-activated T cells can
induce TNF-α synthesis by macrophages in RA through a
mechanism that is dependent on cell contact. Harada and
colleagues showed that freshly isolated cells from synovial
tissues strongly expressed mRNA for IL-15 [18].
Oppenheimer-Marks and colleagues reported that IL-15 is
produced by endothelial cells in RA and that this cytokine
markedly increases the transendothelial migration of both
CD4 and CD8 T cells [19]. Furthermore, they showed that
IL-15 leads to the accumulation of T cells in RA synovial
tissues engrafted into mice with severe combined
immunodeficiency. In a murine model the intra-articular
injection of IL-15 induced a local tissue inflammatory
infiltrate that was predominantly of T lymphocytes.
Disordered overexpression of IL-15 that perpetuates
epithelial damage and promotes the emergence of T cell
clonal proliferations has also been observed in refractory
celiac sprue [5]. In addition, there was a resolution of
psoriasis after blockade of IL-15 activity in a xenograft
mouse model of human psoriasis [4]. IL-15 has also been
suggested to have a pathogenic role in an array of other
chronic inflammatory diseases including sarcoidosis,
chronic hepatitis C and ulcerative colitis. Furthermore,
there was an abnormality of the IL-15–IL-15Rα system
defined in diseases caused by the retrovirus HTLV-I.
Through the action of the HTLV-I-encoded Tax protein
there was transactivation of the genes encoding IL-15 and
IL-15Rα [6]. The interaction of the expressed IL-15 and IL-
15Rα was associated with an autocrine, self-stimulatory,
proliferative loop in patients with the HTLV-I-associated
neurological disease HTLV-I-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) [6]. Furthermore, patients
with this disease had a marked increase in the number of
circulating HLA-A2 restricted antigen-specific (amino acids
11–19 of the HTLV-I-encoded Tax protein), memory and
effector CD8+ T cells that have been suggested to be
involved in the pathogenesis of HAM/TSP. Using ex vivo
cultures of the peripheral blood mononuclear cells from
patients with HAM/TSP, we showed that blockade of IL-15
action resulted in a decrease in the number of such virus-
specific CD8+ cells, supporting the view that in humans, as
in mice, IL-15 is crucial for the maintenance of effector and
memory CD8+ lymphocytes [6].
Opportunities for therapeutic strategies
directed against IL-15 or its receptor
A series of biological agents that block the action of
inflammatory molecules, particularly TNF-α, are being176
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used in the immunotherapy of autoimmune diseases
[7–10]. However, there are limitations to the use of TNF-α
as a target for immunotherapy. Such treatment is not of
value in all patients with RA and does not seem to be
appropriate in the therapy of patients with multiple
sclerosis or HAM/TSP. Another limitation in the use of
TNF-α as a target for immunotherapy is that this cytokine
is not involved in the regulation of immunological memory.
Thus, on withdrawal of TNF-α-directed therapy there is a
high likelihood of the recurrence of the autoimmune
disorder. We propose targeting IL-15 to deal with some of
these limitations, because it is involved in the inflammatory
cascade acting as a major stimulus for TNF-α synthesis
and because, as just noted, it is involved in the
pathogenesis of autoimmune diseases. In particular, IL-15
has been suggested to have a role in the pathogenesis of
HAM/TSP and multiple sclerosis, disorders that are not
responsive to TNF-α-directed immunotherapy [16,20].
Furthermore, IL-15 is the dominant cytokine required for
the maintenance of CD8+ memory T cells [13–15,21]. The
disruption of IL-15 action might interrupt both the
inflammatory components and whatever self-directed
immunological memory exists in autoimmune diseases.
A series of agents that inhibit IL-15 action have been
introduced, including the soluble IL-15Rα chain linked to
the immunoglobulin Fc element, mutant IL-15 molecules,
antibodies directed against IL-15 itself or alternatively
against the IL-2R/IL-15Rβ cytokine receptor subunit
[7–10]. An IL-15 antagonist produced by mutating a
glutamine residue to aspartic acid within the carboxy
terminus of IL-15 inhibited IL-15-triggered cell proliferation
and enhanced the survival of pancreatic islet cell allografts
in mice [8]. The administration of the IL-15 inhibitor, the
soluble IL-15Rα chain, prevented the development of
collagen-induced arthritis in mice [7].
Antibodies against IL-15 have been used effectively in
murine models of autoimmune diseases including
psoriasis [4]. Furthermore, such an antibody has shown
efficacy in a Phase I/Phase II trial involving patients with
RA [9]. Our own IL-15-directed therapeutic approach
involves an antibody humanized MiK-Beta-1 (Hu-MiK-
Beta1) directed against the IL-2R/IL-15Rβ cytokine
receptor that is shared by IL-2 and IL-15 [10]. This
humanized antibody interacts with the IL-2R/IL-15Rβ
receptor subunit and blocks IL-15-mediated stimulation of
NK and T cells ex vivo. Furthermore, the anti-IL-2R/
IL-15Rβ antibody inhibits the action of IL-2 on the
intermediate affinity βγc receptor expressing resting T and
NK cells but does not inhibit the action of IL-2 on cells
expressing high-affinity heterotrimeric IL-2 receptor, such
as regulatory T cells. This antibody, when used as a single
agent, prolonged cardiac allograft survival in cynomolgus
monkeys [10]. Only minimal toxicity was observed in a
Phase I trial that involved patients with T cell large granular
lymphocytic leukemia who were treated with a murine
version of MiK-Beta-1. In an effort to test the hypothesis
that IL-15 has a role in the pathogenesis of select
autoimmune diseases, we are initiating clinical trials with
Hu-MiK-Beta-1 in patients with RA, inflammatory bowel
disease, multiple sclerosis, and such HTLV-I-associated
disorders including HAM/TSP and adult T cell leukemia.
Conclusions
Our emerging understanding of the IL-15/IL-15R system
is providing the scientific basis for the development of
rational approaches for the IL-15-targeted treatment of
autoimmune diseases, disorders associated with the
retrovirus HTLV-I and also selected leukemias and
lymphomas. In particular, given the putative role of IL-15 in
the maintenance of memory CD8+ T cells as well as in the
expression of inflammatory cytokines involved in the
pathogenesis of autoimmune disease, we suggest that the
introduction of strategies that inhibit IL-15 action might
prove to be of great value in the treatment of such T cell-
mediated inflammatory autoimmune disorders.
Competing interest
Thomas A Waldmann holds a US Government patent to
monoclonal antibodies directed against IL-2/IL-15R. No
competing financial interests.
References
1. O’Shea JJ, Ma A, Lipsky P: Cytokines and autoimmunity. Nat
Rev Immunol 2002, 2:37-45.
2. Feldmann M, Brennan FM, Maini RN: Role of cytokines in
rheumatoid arthritis. Annu Rev Imunol 1996, 14:397-440.
3. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY: Inter-
leukin-15 mediates T cell-dependent regulation of tumor
necrosis factor-alpha production in rheumatoid arthritis. Nat
Med 1997, 3:189-195.
4. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-
Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF,
van Dijk MA, Parren PWHI, Baadsgaard O, van de Winkel JGJ:
Resolution of psoriasis upon blockade of IL-15 biological
activity in a xenograft-mouse model. J Clin Invest 2003, 112:
1571-1580.
5. Mention, JJ, Ahmed, MB, Bégue B, Barbe U, Verkarre V, Asnafi V,
Colombel JF, Cugnenc PH, Ruemmele FM, McIntyre E, Brousse
N, Cellier C, and Cerf-Bensussan N: Interleukin 15: a key to dis-
rupted intraepithelial lymphocyte hemostasis and lymphoma-
genesis in celiac disease. Gastroenterology 2003,  125:
730-745.
6. Azimi N, Nagai M, Jacobson S, Waldmann TA: IL-15 plays a
major role in the persistence of Tax-specific CD8 cells in
HAM/TSP patients. Proc Natl Acad Sci USA 2001, 98:14559-
14564
7. Ruchatz H, Leung BP, Wei XQ, McInnes IB, and Liew FY:
Soluble IL-15 receptor alpha-chain administration prevents
murine collagen-induced arthritis: a role for IL-15 in develop-
ment of antigen-induced immunotherapy. J Immunol 1998,
160:5654-5660.
8. Kim YS, Maslinski W, Zheng XX, Stevens AC, Li XC, Tesch GH,
Kelley VR, Strom TB: Targeting the IL-15 receptor with an
antagonist IL-15 mutant/Fc γ γ2a protein blocks delayed-type
hypersensitivity. J Immunol 1998, 160: 5742-5748.
9. Baslund B, Tvede N, Danneskiold-Samsoe B, Petersen J,
Petersen LJ, Schuurman J, de Winkel JV, Larsson P, Panayi G,
McInnes LB: A novel human monoclonal antibody against IL-
15 (humax-IL15) in patients with active rheumatoid arthritis
(RA): results of a double-blind, placebo-controlled phase I/II
trial. Arthritis Rheum 2003, Suppl S:1706.177
10. Tinubu SA, Hakimi J, Kondas JA, Bailon P, Familletti PC, Spence
C, Crittendon MD, Parenteau GL, Dirbas FM, Tsudo M, Bacher
JD, Kasten-Sportès C, Martinucci JL, Goldman CK, Clark RE,
Waldmann TA: A humanized antibody directed to the inter-
leukin-2 receptor beta-chain prolongs primate cardiac allo-
graft survival. J Immunol 1994, 153:4330-4338.
11. Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman
CK, Brennan J, Roessler E, Waldmann TA: The interleukin (IL) 2
receptor beta chain is shared by IL-2 and a cytokine, provi-
sionally designated IL-T, that stimulates T-cell proliferation
and the induction of lymphokine-activated killer cells. Proc
Natl Acad Sci USA 1994, 91:4940-4944.
12. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S,
Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M,
Johnson L, Alderson MR, Watson JD, Anderson DM, Giri JG:
Cloning of a T cell growth factor that interacts with the beta
chain of the interleukin-2 receptor. Science 1994,  264:965-
968.
13. Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2
and IL-15 in the life and death of lymphocytes: implications
for immunotherapy. Immunity 2001, 14:105-110.
14. Zhang X, Sun S, Hwang l, Tough DF, Sprent J: Potent and selec-
tive stimulation or memory-phenotype CD8+ T cells in vivo by
IL-15. Immunity 1998, 8:591-599.
15. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P: Control
of homeostasis of CD8+ memory T cells by opposing
cytokines. Science 2000, 288: 675-678.
16. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW: Inter-
leukin-2 receptor α α chain regulates the size and content of
the peripheral lymphoid compartment. Immunity 1995, 3:521-
530.
17. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulis T, Trettin
S, Ma A.: IL-15 receptor maintains lymphoid hemeostatsis by
supporting lymphocyte homing and proliferation. Immunity
1998, 9:668-676.
18. Harada S, Yamamura M, Okamoto H. Morita Y, Kawahima M, Aita
T, Makino Y. Production of interleukin-7 and interleukin-15 by
fibroblast-like synoviocytes from patients with rheumatoid
arthritis. Arthritis Rheum 1999, 42:1508-1516.
19. Oppenheimer-Marks N, Brezinschek RL, Mohamadzadeh M, Vita
R, Lipsky PE: Interleukin 15 is produced by endothelial cells
and increases the transendothelial migration of T cells in vitro
and in the SCID mouse-human rheumatoid arthritis model in
vivo. J Clin Invest 1998, 101:1261-1272.
20. Losy J, Niezgoda A, Zaremba J: IL-15 is elevated in sera of
patients with relapsing-remitting multiple sclerosis. Folia Neu-
ropathol 2002, 40:151-153.
21. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada J,
Feigenbaum L, Waldmann TA, Tagaya Y: IL-2 induced activa-
tion-induced cell death is inhibited in IL-15 transgenic mice.
Proc Natl Acad Sci USA 2000, 97:11445-11450.
Available online http://arthritis-research.com/content/6/4/174